The IRF2BP1 (Interferon Regulatory Factor 2 Binding Protein 1) antibody is a tool used to detect and study the IRF2BP1 protein, a transcriptional corepressor involved in immune regulation and cellular processes. IRF2BP1 interacts with interferon regulatory factor 2 (IRF2), a key player in modulating interferon (IFN)-mediated immune responses. This interaction suppresses IRF2-dependent transcriptional activation, influencing pathways critical for inflammation, apoptosis, and immune cell differentiation. IRF2BP1 also regulates other transcription factors, such as nuclear factor-κB (NF-κB) and β-catenin, linking it to broader signaling networks in cancer, autoimmune disorders, and viral infections.
Antibodies targeting IRF2BP1 are typically developed in hosts like rabbits or mice, using immunogens derived from specific regions of the human IRF2BP1 protein. These antibodies are validated for applications such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and immunoprecipitation (IP) to assess protein expression, localization, and interactions. Studies using IRF2BP1 antibodies have revealed its nuclear or cytoplasmic localization, depending on cell type and context, and its dysregulation in diseases like hepatocellular carcinoma and cardiovascular disorders.
Research with IRF2BP1 antibodies contributes to understanding its role in immune tolerance, tumor suppression, and transcriptional repression mechanisms. Its involvement in pathways like Wnt/β-catenin and NF-κB underscores its potential as a therapeutic target or biomarker in inflammatory and malignant conditions.